Angio-based Final Functional Effect of PCI

Last updated: February 2, 2024
Sponsor: Medical University of Warsaw
Overall Status: Active - Recruiting

Phase

N/A

Condition

Heart Disease

Angina

Chest Pain

Treatment

Angiography-based vessel fractional flow reserve (vFFR) calculation

Clinical Study ID

NCT06255678
AFFE-PCI
  • Ages > 18
  • All Genders

Study Summary

Fractional flow reserve (FFR) has revolutionized the diagnosis and treatment of coronary artery disease (CAD), and more recently, post percutaneous coronary intervention (post-PCI) FFR has emerged as an independent predictor of cardiovascular events, enabling the identification of cases requiring additional optimization of the implanted stent. Modern technologies allow less invasive alternatives to traditional FFR measurement - angiography-based vessel fractional flow reserve (vFFR) and derivative ΔvFFR, which is calculated by a difference between the post-PCI vFFR and pre-PCI vFFR. In large clinical studies, the good accuracy between vFFR and FFR - measured before and after PCI - has been confirmed. However, insufficient data is available about the value of post-vFFR and ΔvFFR as prognostic values and indicators of patient health.

This is a prospective multicenter register study analyzing the association between the value of ΔvFFR, vFFR after PCI and adverse clinical outcomes, residual angina and quality of life using the validated Seattle Angina Questionnaire (SAQ) and EuroQol 5-level 5-dimensional questionnaire (EQ-5D-5L). Patients undergoing PCI for chronic coronary syndromes (CCS), non-ST-segment elevation acute coronary syndromes (NST-ACS) or ST-Segment Elevation Myocardial Infarction (STEMI) will be enrolled in this study.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Percutaneous coronary intervention (PCI) for chronic coronary syndromes (CCS) or acutecoronary syndromes (ACS)
  • Adequate quality of angiogram enabling vFFR analysis (available two angiographic viewswith ≥30° differences in rotation/angulation, the possibility of vessel contourselection, proper quality of the images, vessels without severe overlapping,tortuosity, foreshortening and poor vessel opacification)
  • Age >18 years
  • The patient's written informed consent has been obtained before the procedure

Exclusion

Exclusion Criteria:

  • Cardiogenic shock, pulmonary oedema
  • Severe hemodynamical instability
  • Prior coronary artery bypass grafting (CABG)
  • Active bleeding
  • Acute and chronic inflammatory conditions
  • Acute mechanical complications of myocardial infarction
  • Congenital heart disease
  • Heart transplantation
  • Non-cardiac comorbidities with a life expectancy of less than 1 year

Study Design

Total Participants: 2005
Treatment Group(s): 1
Primary Treatment: Angiography-based vessel fractional flow reserve (vFFR) calculation
Phase:
Study Start date:
July 03, 2023
Estimated Completion Date:
January 01, 2027

Study Description

The primary goal of this prospective multicenter register study is to evaluate the association between the value of vFFR after PCI and adverse clinical outcomes, residual angina and quality of life using the validated Seattle Angina Questionnaire (SAQ) and EuroQol 5-level 5-dimensional questionnaire (EQ-5D-5L) at 6 and 24 months following PCI. The primary composite endpoint is defined as a major adverse cardiovascular event (MACE) including all-cause death, target-vessel myocardial infarction (TVMI), and target vessel revascularization (TVR)] at 6, 12 and 24-month follow-ups. Patients undergoing PCI for chronic coronary syndromes (CCS), non-ST-segment elevation acute coronary syndromes (NST-ACS) or or ST-Segment Elevation Myocardial Infarction (STEMI) will be enrolled in this study. The analyses of the primary endpoint will be stratified according to the following subgroups:

  • Diabetes/non-diabetes

  • Glomerular filtration rate (GFR)≥60/GFR<60 [ml/min./1,73m2]

  • Focal/diffuse atherosclerosis

  • Multivessel/single-vessel disease

  • CCS/NST-ACS/STEMI

  • CCS/ACS

The patients' coronary angiograms will be analyzed using a CAAS workstation (Pie Medical Imaging, Maastricht, the Netherlands) enrolled at the Invasive Cardiology Unit of the 1st Department of Cardiology, Medical University of Warsaw (Poland) and other centers in Poland.

Connect with a study center

  • Medical University of Warsaw

    Warsaw, 02-097
    Poland

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.